Your browser doesn't support javascript.
loading
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Bahçeci, Aykut; Paydas, Semra; Ak, Naziye; Ferhatoglu, Ferhat; Saip, Pinar Mualla; Seydaoglu, Gülsah; Bilici, Mehmet; Simsek, Melih; Tekin, Salim Basol; Çalikusu, Züleyha; Yavuz, Sinan; Sahin, Ahmet Bilgehan; Çubukçu, Erdem; Evrensel, Türkkan; Degirmencioglu, Serkan; Demiray, Atike Gökçen; Yumuk, Perran Fulden; Alan, Özkan; Çikman, Duygu Ilke; Demirelli, Fuat Hulusi; Köstek, Osman; Gökyer, Ali; Dogan, Mutlu; Bal, Öznur; Çakar, Burcu; Gökmen, Erhan; Yamaç, Deniz; Korkmaz, Taner; Aliyev, Altay; Keskin, Özge; Urvay, Semiha; Büyüksimsek, Mahmut; Karadeniz, Cemile; Yildiz, Birol; Çinkir, Havva Yesil; Demir, Hacer; Beypinar, Ismail; Karaçin, Cengiz; Eser, Kadir; Baykara, Meltem; Kiliçkap, Saadettin; Okutur, Kerem; Bulut, Gülcan; Alkan, Ali; Arpaci, Erkan; Pilanci, Kezban Nur; Demir, Atakan; Isik, Deniz; Yildirim, Nilgün.
Afiliação
  • Bahçeci A; Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey.
  • Paydas S; Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey.
  • Ak N; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Ferhatoglu F; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Saip PM; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Seydaoglu G; Department of Biostatistics, University of Cukurova, Adana, Turkey.
  • Bilici M; Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.
  • Simsek M; Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.
  • Tekin SB; Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.
  • Çalikusu Z; Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, Turkey.
  • Yavuz S; Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, Turkey.
  • Sahin AB; Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
  • Çubukçu E; Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
  • Evrensel T; Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
  • Degirmencioglu S; Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
  • Demiray AG; Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
  • Yumuk PF; Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Alan Ö; Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Çikman DI; Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
  • Demirelli FH; Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
  • Köstek O; Department of Medical Oncology, Trakya University, Edirne, Turkey.
  • Gökyer A; Department of Medical Oncology, Trakya University, Edirne, Turkey.
  • Dogan M; Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Bal Ö; Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Çakar B; Department of Medical Oncology, Ege University, Izmir, Turkey.
  • Gökmen E; Department of Medical Oncology, Ege University, Izmir, Turkey.
  • Yamaç D; Department of Medical Oncology, Ankara Güven Hospital, Ankara, Turkey.
  • Korkmaz T; Acibadem MAA University School of Medicine, Medical Oncology Division, Acibadem Research Institiute of Senology (Maslak Hospital).
  • Aliyev A; Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, Turkey.
  • Keskin Ö; Department of Medical Oncology, Selçuk University, Konya, Turkey.
  • Urvay S; Department of Medical Oncology, Acibadem Kayseri Hospital, Acibadem MAA University, Kayseri, Turkey.
  • Büyüksimsek M; Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey.
  • Karadeniz C; Department of Medical Oncology, Hatay Antakya State Hospital, Hatay, Turkey.
  • Yildiz B; Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Çinkir HY; Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey.
  • Demir H; Department of Medical Oncology, Kayseri Education and Research Hospital.
  • Beypinar I; Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyonkarahisar, Turkey.
  • Karaçin C; Department of Medical Oncology, Ankara Diskapi Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Eser K; Department of Medical Oncology, Mersin University, Mersin, Turkey.
  • Baykara M; Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
  • Kiliçkap S; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Okutur K; Department of Medical Oncology, Istanbul Memorial Bahcelievler Hospital, Istanbul, Turkey.
  • Bulut G; Department of Medical Oncology, Antakya Defne Hospital, Hatay, Turkey.
  • Alkan A; Department of Medical Oncology, Mugla Sitki Kocman University, Mugla, Turkey.
  • Arpaci E; Department of Medical Oncology, Kocaeli Gebze Medicalpark Hospital, Kocaeli, Turkey.
  • Pilanci KN; Department of Medical Oncology, Istanbul Aydin University, Istanbul, Turkey.
  • Demir A; Department of Medical Oncology, Ankara Güven Hospital, Ankara, Turkey.
  • Isik D; Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey.
  • Yildirim N; Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey.
Cancer Invest ; 39(6-7): 473-481, 2021.
Article em En | MEDLINE | ID: mdl-34014777
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Antineoplásicos Imunológicos / Ado-Trastuzumab Emtansina Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Cancer Invest Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Antineoplásicos Imunológicos / Ado-Trastuzumab Emtansina Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Cancer Invest Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia